Diagnostic Importance of CA-125 in Detection of Recurrence and Progress of the Disease in Stages III and IV of Epithelial Ovarian Carcinoma

Diagnostic Importance of CA-125 in Detection of Recurrence and Progress of the Disease in Stages III and IV of Epithelial Ovarian Carcinoma

In 60 patients operated in stages III and IV of epithelial ovarian carcinoma continuous determination of CA 125 from serum was done during the following 2 years. The main condition for entering the survey were elevated values of CA 125 in serum > 35 U/mL and histologically verified epithelial ovarian carcinoma. The aim of the survey was to perform statistical assessment of serum CA 125 determination in diagnostics of recurrence and progression of the disease in stages III and IV of epithelial ovarian carcinoma, and percentage (%) of false positive and negative results. Determination of CA 125 from serum during 2 postoperative years is a reliable but not completely certain diagnostic parameter in detection of the disease progression in stages III and IV of epithelial ovarian carcinoma (sensitivity 79.3%, specificity 97.1%, positive predictive value 91.2%, negative predictive value 92.4%, test accuracy 92.1%). False positive (0.7%) and false negative results (4.7%) of individual tests were present in 5.4% of all samples.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Bast RC, Feeney M, Lazarus HE T, Nadler L, Colvin R, Knapp R. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-7.

  • Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY. The utility of presurgical CA 125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 2006; 16, 496-500.

  • Cooper BC, Sood AK, Davis CS, Berliare M, Brady MF. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002; 100: 59-64.

  • Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ S, Sokletormos G, Torre GC, Tuxen MK, Zwirner M. CA 125 in Ovarian Cancer: European Group On Tumor Markers: Guidelines for Clinical Use. Int J Gynecol Cancer 2005; 15, 679-91.

  • Tuxen MK, Soletormos G, Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001; 84: 1301-7.

  • Đurđević S, Đurđević J. Tumorski markeri u ginekološkoj onkologiji. 1. izd. Beograd: Društvo medicinskih biohemičara Jugoslavije, 1998; 118.

  • Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 2003; 65: 1-6.

  • Majkić-Singh N. Tumorski markeri: biohemija i klasifikacija. Jugoslov Med Biohem 2006; 25 (2): 79.

  • Jacobs I, Skates SJ, MacDonald N, Bridges J, Davies AP. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207-10.

  • ACOG Committee Opinion. The role of the generalist obstetritian-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100: 1413-6.

  • Board RE, Brujins CT PH, Pronk AE, Ryder WD J, Wilkinson PM, Welch R, Shanks JH, Connolly G, Slade RJ, Reynolds K, Kitchener HC, Jayson GC. Stage and CA 125 related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer 2006; 16 (Suppl.1), 18-24.

  • Skates SJ, Menon U, MacDonald N. Calculation of the risk of ovarian cancer from serial CA 125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21: 206-10.

  • Schlegel G, Lauthagens M. Assessment of marker results. In: Luthagens M, Schlegel G. Clinical use of the tumor marker system CEA-TPA. 1. ed. Stuttgart: Tumour Diagnostik Verlag, 1989; 1-10.

  • Stanković S. Tumorski markeri: metode određivanja. Jugoslov Med Biohem 2006; 25 (2): 89-101.

  • Sheps BS, Schechter T. The assesment of diagnostic test. JAMA YU. 1985; 1(2): 204-8.

  • Aslan D, Sandberg S. Simple statistics in diagnostic tests. Journal Medical Biochem 2007; 26 (4): 309-13.

  • Rustin GJ S. Use of CA125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21: 187s-93s.

  • Rim SY, Kim SM, Choi HS. Struma ovarii showing clinical characteristics of ovarian malignancy. Int J Gynecol Cancer 2005; 15, 1156-9.

  • Eisenhauer EA, Vermorken JB, Van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963-8.

  • Tuxen MK, Soletormos G, Dombernowsky P. Serum tumor marker CA 125 for monitoring ovarian cancer during follow up. Scand J Clin Lab Invest 2002; 62: 177-88.

  • Rustin GJ S, Marples M, Nelstrop EA, Tuxen MK, Lambert HE. Use of CA 125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 10: 4054-7.

  • Murakami M, Miyamoto T, Iida T, Tsukada H, Watanabe M, Shida M, Maeda H, Nasu S, Yasuda S, Yasuda M, Ide M. Whole-body positron emission tomography and tumor marker CA 125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006, 16 (Suppl.1), 99-107.

  • Skates SJ, Menon U, MacDonald N, Xy FJ, YU YH. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21: 206-10.

  • Mayer T, Rustin GJ. Role of the Tumour Markers in monitoring Epithelial Ovarian Cancer. Br J Cancer 2000; 82: 1535-8.

  • Mousavi AS, Borna S, Moeinoddini S. Estimation of probability of malignancy using a logistic model combining color Doppler ultrasonography, serum CA 125 level in women with a pelvic mass. Int J Gynecol Cancer 2006; 16 (Suppl.1): 92-98.